Unnamed: 0,title,date,stock,sentiment
1022930.0,"Raymond James Maintains Outperform on Insulet, Lowers Price Target to $200",2020-06-09 07:17:00-04:00,PODD,negative
1022931.0,Insulet Reports Resumption Of Pivotal Study Of Omnipod,2020-06-05 06:06:00-04:00,PODD,neutral
1022932.0,75 Biggest Movers From Yesterday,2020-05-14 04:26:00-04:00,PODD,neutral
1022933.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,PODD,negative
1022934.0,50 Stocks Moving In Wednesday's Mid-Day Session,2020-05-13 12:41:00-04:00,PODD,neutral
1022935.0,50 Stocks Moving In Wednesday's Mid-Day Session,2020-05-13 12:41:00-04:00,PODD,neutral
1022936.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,PODD,neutral
1022937.0,30 Stocks Moving in Wednesday's Pre-Market Session,2020-05-13 07:17:00-04:00,PODD,neutral
1022938.0,"5 Stocks To Watch For May 13, 2020",2020-05-13 04:40:00-04:00,PODD,neutral
1022939.0,Insulet Corp Announces Plans For A Public Offering Of Its Common Stock,2020-05-12 16:22:00-04:00,PODD,neutral
1022940.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,PODD,negative
1022941.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,PODD,neutral
1022942.0,"CFRA Reiterates Sell on Insulet, Raises Price Target to $179",2020-05-08 13:56:00-04:00,PODD,neutral
1022943.0,"Stifel Maintains Hold on Insulet, Raises Price Target to $195",2020-05-08 13:34:00-04:00,PODD,neutral
1022944.0,"UBS Maintains Neutral on Insulet, Raises Price Target to $213",2020-05-08 13:32:00-04:00,PODD,neutral
1022945.0,"JP Morgan Maintains Overweight on Insulet, Raises Price Target to $235",2020-05-08 12:17:00-04:00,PODD,neutral
1022946.0,"Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $222",2020-05-08 08:54:00-04:00,PODD,neutral
1022947.0,Insulet shares are trading lower after the company reported Q1 EPS results down from last year.,2020-05-08 07:34:00-04:00,PODD,neutral
1022948.0,"Citigroup Maintains Buy on Insulet, Raises Price Target to $250",2020-05-08 07:27:00-04:00,PODD,neutral
1022949.0,"SVB Leerink Maintains Market Perform on Insulet, Raises Price Target to $230",2020-05-08 06:32:00-04:00,PODD,neutral
1022950.0,"Insulet Q1 EPS $(0.030) Down From $0.070 YoY, Sales $198.000M Beat $189.820M Estimate",2020-05-07 16:06:00-04:00,PODD,neutral
1022951.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,PODD,negative
1022952.0,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.,2020-05-05 12:44:00-04:00,PODD,positive
1022953.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,PODD,neutral
1022954.0,"Raymond James Maintains Outperform on Insulet, Raises Price Target to $220",2020-04-27 11:37:00-04:00,PODD,neutral
1022955.0,"Benzinga's Top Upgrades, Downgrades For April 24, 2020",2020-04-24 09:38:00-04:00,PODD,positive
1022956.0,Insulet shares are trading lower after SVB Leerink downgraded the stock from Outperform to Market Perform.,2020-04-24 08:12:00-04:00,PODD,neutral
1022957.0,SVB Leerink Downgrades Insulet to Market Perform,2020-04-24 07:43:00-04:00,PODD,neutral
1022958.0,Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.,2020-04-23 11:27:00-04:00,PODD,positive
1022959.0,"Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $186",2020-03-27 09:39:00-04:00,PODD,neutral
1022960.0,"Citigroup Maintains Buy on Insulet, Lowers Price Target to $206",2020-03-27 09:05:00-04:00,PODD,negative
1022961.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2020",2020-03-05 10:05:00-05:00,PODD,positive
1022962.0,"Citigroup Initiates Coverage On Insulet with Buy Rating, Announces $220 Price Target",2020-03-05 04:59:00-05:00,PODD,neutral
1022963.0,"Hearing Citi Initiates Coverage On J&J, Boston Scientific, Zimmer Biomet, Stryker, Medtronic, Insulet With Buy Ratings",2020-03-04 17:47:00-05:00,PODD,neutral
1022964.0,Insulet shares are trading lower after the company announced its plan to pause its pivotal study of Omnipod Horizon Automated Glucose Control System to correct software anomaly.,2020-03-03 11:54:00-05:00,PODD,neutral
1022965.0,Insulet Says Plans to Pause Pivotal Study of Omnipod Horizon Automated Glucose Control System to Correct Software Anomaly,2020-03-02 06:06:00-05:00,PODD,neutral
1022966.0,95 Biggest Movers From Yesterday,2020-02-27 05:18:00-05:00,PODD,neutral
1022967.0,"CFRA Maintains Sell on Insulet, Lowers Price Target to $162",2020-02-26 13:28:00-05:00,PODD,negative
1022968.0,75 Stocks Moving In Wednesday's Mid-Day Session,2020-02-26 12:18:00-05:00,PODD,neutral
1022969.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,PODD,negative
1022970.0,"Baird Maintains Outperform on Insulet, Lowers Price Target to $215",2020-02-26 09:22:00-05:00,PODD,negative
1022971.0,Insulet shares are trading lower after the company reported worse-than-expected Q4 EPS results.,2020-02-26 09:08:00-05:00,PODD,neutral
1022972.0,"Raymond James Maintains Outperform on Insulet, Lowers Price Target to $205",2020-02-26 07:21:00-05:00,PODD,negative
1022973.0,44 Stocks Moving in Wednesday's Pre-Market Session,2020-02-26 07:20:00-05:00,PODD,neutral
1022974.0,14 Stocks Moving In Tuesday's After-Hours Session,2020-02-25 16:48:00-05:00,PODD,neutral
1022975.0,Insulet shares are trading lower after the company reported worse-than-expected Q4 EPS results.,2020-02-25 16:07:00-05:00,PODD,neutral
1022976.0,"Insulet Q4 EPS $0.08 Misses $0.11 Estimate, Sales $209.4M Beat $199.5M Estimate",2020-02-25 16:01:00-05:00,PODD,negative
1022977.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,PODD,negative
1022978.0,"Earnings Scheduled For February 25, 2020",2020-02-25 04:26:00-05:00,PODD,neutral
1022979.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,PODD,neutral
1022980.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,PODD,negative
1022981.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-19 10:32:00-05:00,PODD,neutral
1022982.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,PODD,negative
1022983.0,Dexcom And Insulet Announce Commercial Agreement To Integrate The Dexcom G6 And Future G7 CGM Into Insulet's Omnipod Horizon Automated Insulin Delivery System,2020-02-19 07:10:00-05:00,PODD,positive
1022984.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-18 11:03:00-05:00,PODD,neutral
1022985.0,Stocks That Hit 52-Week Highs On Friday,2020-02-14 10:15:00-05:00,PODD,neutral
1022986.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,PODD,negative
1022987.0,Insulet Reports Medical Device Correction For Omnipod DASH,2020-02-13 06:13:00-05:00,PODD,neutral
1022988.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,PODD,positive
1022989.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,PODD,neutral
1022990.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,PODD,positive
1022991.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,PODD,negative
1022992.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,PODD,negative
1022993.0,"Raymond James Maintains Outperform on Insulet, Raises Price Target to $213",2020-02-06 07:27:00-05:00,PODD,neutral
1022994.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,PODD,neutral
1022995.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-04 10:18:00-05:00,PODD,neutral
1022996.0,Stocks That Hit 52-Week Highs On Friday,2020-01-31 10:23:00-05:00,PODD,neutral
1022997.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,PODD,positive
1022998.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-29 10:16:00-05:00,PODD,neutral
1022999.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,PODD,neutral
1023000.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-28 11:05:00-05:00,PODD,neutral
1023001.0,Stocks That Hit 52-Week Highs On Friday,2020-01-24 10:41:00-05:00,PODD,neutral
1023002.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,PODD,positive
1023003.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-22 10:17:00-05:00,PODD,neutral
1023004.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,PODD,negative
1023005.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,PODD,neutral
1023006.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,PODD,neutral
1023007.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,PODD,neutral
1023008.0,"JP Morgan Maintains Overweight on Insulet, Raises Price Target to $200",2019-12-20 09:36:00-05:00,PODD,neutral
1023009.0,"Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $181",2019-12-17 09:09:00-05:00,PODD,neutral
1023010.0,Watching shares of DexCom And Insulet After Rival Tandem Received FDA Marketing Authorization For Diabetes Care Control-IQ Technology,2019-12-13 11:56:00-05:00,PODD,positive
1023011.0,"Canaccord Genuity Maintains Hold on Insulet, Raises Price Target to $165",2019-12-09 10:45:00-05:00,PODD,neutral
1023012.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,PODD,negative
1023013.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-27 10:14:00-05:00,PODD,neutral
1023014.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,PODD,negative
1023015.0,Insulet shares are trading higher. Not seeing any news to justify the price action.,2019-11-25 14:30:00-05:00,PODD,positive
1023016.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,PODD,positive
1023017.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-20 10:12:00-05:00,PODD,neutral
1023018.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,PODD,neutral
1023019.0,Stocks That Hit 52-Week Highs On Monday,2019-11-18 11:01:00-05:00,PODD,neutral
1023020.0,"Piper Jaffray Maintains Overweight on Insulet, Raises Price Target to $200",2019-11-18 07:56:00-05:00,PODD,negative
1023021.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,PODD,positive
1023022.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,PODD,neutral
1023023.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-12 10:11:00-05:00,PODD,neutral
1023024.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,PODD,neutral
1023025.0,Insulet shares are trading higher on continued momentum after the stock reported better-than-expected Q3 earnings results 2 days ago.,2019-11-08 11:33:00-05:00,PODD,positive
1023026.0,60 Biggest Movers From Yesterday,2019-11-07 05:44:00-05:00,PODD,neutral
1023027.0,"Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $148",2019-11-06 09:05:00-05:00,PODD,neutral
1023028.0,"Baird Maintains Outperform on Insulet, Raises Price Target to $170",2019-11-06 08:53:00-05:00,PODD,neutral
1023029.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,PODD,positive
1023030.0,"Raymond James Maintains Outperform on Insulet, Raises Price Target to $158",2019-11-06 07:52:00-05:00,PODD,neutral
1023031.0,Insulet Sees Q4 Sales Guidance $193M-$201M vs $194.82M Est.,2019-11-05 16:43:00-05:00,PODD,neutral
1023032.0,Insulet Raises FY19 Sales Guidance From $700M-$715M To $722M-$730M vs $711.48M Est.,2019-11-05 16:42:00-05:00,PODD,neutral
1023033.0,"Insulet Q3 EPS $0.09 Beats $0.04 Estimate, Sales $192.115M Beat $179.53M Estimate",2019-11-05 16:40:00-05:00,PODD,neutral
1023034.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,PODD,negative
1023035.0,"Insulet Reports FDA Cleared Fiasp With Omnipod Insulin Mgmt. System, Omnipod DASH",2019-10-25 06:14:00-04:00,PODD,positive
1023036.0,"Stifel Initiates Coverage On Insulet with Hold Rating, Announces $163 Price Target",2019-10-23 06:55:00-04:00,PODD,neutral
1023037.0,10 Biggest Price Target Changes For Friday,2019-10-18 08:55:00-04:00,PODD,neutral
1023038.0,"Canaccord Genuity Downgrades Insulet to Hold, Raises Price Target to $145",2019-10-18 06:36:00-04:00,PODD,neutral
1023039.0,"Benzinga's Top Upgrades, Downgrades For October 14, 2019",2019-10-14 10:46:00-04:00,PODD,positive
1023040.0,BTIG Downgrades Insulet to Neutral,2019-10-14 06:48:00-04:00,PODD,neutral
1023041.0,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,2019-10-11 11:19:00-04:00,PODD,positive
1023042.0,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,2019-10-08 10:36:00-04:00,PODD,positive
1023043.0,"Benzinga's Top Upgrades, Downgrades For October 4, 2019",2019-10-04 09:51:00-04:00,PODD,positive
1023044.0,10 Biggest Price Target Changes For Friday,2019-10-04 08:45:00-04:00,PODD,neutral
1023045.0,"UBS Downgrades Insulet to Neutral, Raises Price Target to $160",2019-10-04 07:11:00-04:00,PODD,neutral
1023046.0,"Benzinga's Top Upgrades, Downgrades For October 3, 2019",2019-10-03 10:07:00-04:00,PODD,positive
1023047.0,Guggenheim Securities Downgrades Insulet to Neutral,2019-10-03 08:54:00-04:00,PODD,positive
1023048.0,Guggenheim Downgrades Insulet to Neutral,2019-10-03 06:41:00-04:00,PODD,neutral
1023049.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,2019-10-02 10:33:00-04:00,PODD,negative
1023050.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,PODD,negative
1023051.0,Stocks That Hit 52-Week Highs On Monday,2019-09-30 11:10:00-04:00,PODD,neutral
1023052.0,"SVB Leerink Maintains Outperform on Insulet, Raises Price Target to $185",2019-09-24 08:26:00-04:00,PODD,neutral
1023053.0,Insulet's Insulin Delivery System Receives FDA Clearance As ACE Pump For Drug Infusion,2019-09-23 11:00:00-04:00,PODD,neutral
1023054.0,Insulet Receives Clearance from the FDA for an Alternate Controller Enabled Infusion Pump,2019-09-23 06:41:00-04:00,PODD,neutral
1023055.0,60 Biggest Movers From Yesterday,2019-09-05 05:20:00-04:00,PODD,neutral
1023056.0,46 Stocks Moving In Wednesday's Mid-Day Session,2019-09-04 12:27:00-04:00,PODD,neutral
1023057.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-09-04 07:56:00-04:00,PODD,neutral
1023058.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,PODD,positive
1023059.0,66 Biggest Movers From Yesterday,2019-09-04 05:07:00-04:00,PODD,neutral
1023060.0,Stocks That Hit 52-Week Highs On Friday,2019-08-23 10:33:00-04:00,PODD,neutral
1023061.0,Stocks That Hit 52-Week Highs On Thursday,2019-08-22 10:32:00-04:00,PODD,neutral
1023062.0,Stocks That Hit 52-Week Highs Of Monday,2019-08-12 10:31:00-04:00,PODD,neutral
1023063.0,Stocks That Set New 52-Week Highs Thursday,2019-08-08 12:19:00-04:00,PODD,neutral
1023064.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,PODD,neutral
1023065.0,85 Biggest Movers From Yesterday,2019-08-07 05:39:00-04:00,PODD,neutral
1023066.0,68 Stocks Moving In Tuesday's Mid-Day Session,2019-08-06 13:55:00-04:00,PODD,neutral
1023067.0,"Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $135",2019-08-06 11:02:00-04:00,PODD,neutral
1023068.0,New 52-Week-High Achievers For Tuesday Morning,2019-08-06 10:23:00-04:00,PODD,neutral
1023069.0,"Benzinga's Top Upgrades, Downgrades For August 6, 2019",2019-08-06 09:49:00-04:00,PODD,positive
1023070.0,Insulet shares are trading higher after the company reported better-than-expected Q2 sales results. The company also raised FY19 sales guidance above analyst estimates.,2019-08-06 09:45:00-04:00,PODD,positive
1023071.0,"BMO Capital Maintains Outperform on Insulet, Raises Price Target to $150",2019-08-06 08:54:00-04:00,PODD,neutral
1023072.0,10 Biggest Price Target Changes For Tuesday,2019-08-06 08:53:00-04:00,PODD,neutral
1023073.0,30 Stocks Moving In Tuesday's Pre-Market Session,2019-08-06 07:55:00-04:00,PODD,neutral
1023074.0,"Raymond James Maintains Outperform on Insulet, Raises Price Target to $135",2019-08-06 07:28:00-04:00,PODD,neutral
1023075.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,PODD,positive
1023076.0,"JP Morgan Upgrades Insulet to Overweight, Raises Price Target to $155",2019-08-06 06:27:00-04:00,PODD,neutral
1023077.0,Insulet shares are trading higher after the company reported better-than-expected Q2 sales results. The company also raised FY19 sales guidance above analyst estimates.,2019-08-05 16:38:00-04:00,PODD,positive
1023078.0,Insulet Raises FY19 Sales Guidance From $667M-$690M To $700M-$715M vs $684.6M Estimate,2019-08-05 16:04:00-04:00,PODD,neutral
1023079.0,"Insulet Q2 EPS $0.02, Inline, Sales $177.1M Beat $163.66M Estimate",2019-08-05 16:04:00-04:00,PODD,neutral
1023080.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,PODD,neutral
1023081.0,"The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster",2019-07-31 07:06:00-04:00,PODD,negative
1023082.0,Companies That Achieved 52-Week Highs Friday,2019-07-26 15:37:00-04:00,PODD,neutral
1023083.0,"Morgan Stanley Maintains Equal-Weight on Insulet, Raises Price Target to $127",2019-07-16 08:47:00-04:00,PODD,neutral
1023084.0,"The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study",2019-07-12 07:24:00-04:00,PODD,negative
1023085.0,"JP Morgan Maintains Neutral on Insulet, Raises Price Target to $120",2019-06-27 09:31:00-04:00,PODD,positive
1023086.0,"The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge",2019-06-20 07:25:00-04:00,PODD,positive
1023087.0,"The Daily Biotech Pulse:  Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA",2019-06-14 08:47:00-04:00,PODD,neutral
1023088.0,10 Biggest Price Target Changes For Thursday,2019-06-13 10:02:00-04:00,PODD,neutral
1023089.0,"UBS Maintains Buy on Insulet, Raises Price Target to $130",2019-06-13 08:45:00-04:00,PODD,neutral
1023090.0,"The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes",2019-06-13 07:44:00-04:00,PODD,negative
1023091.0,Northland Downgrades Insulet to Market Perform,2019-06-10 09:08:00-04:00,PODD,neutral
1023092.0,Insulet Announces Omnipod Horizon Hybrid Closed-Loop System Improves Glycemic Control in Patients as Young as Two Years Old with Type 1 Diabetes at ADA Scientific Sessions,2019-06-10 03:58:00-04:00,PODD,positive
1023093.0,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache",2019-06-05 07:30:00-04:00,PODD,positive
1023094.0,"The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation",2019-05-29 07:38:00-04:00,PODD,neutral
1023095.0,"Benzinga's Top Upgrades, Downgrades For May 6, 2019",2019-05-06 09:11:00-04:00,PODD,positive
1023096.0,BTIG Research Upgrades Insulet Corporation - Common Stock to Buy,2019-05-06 06:26:00-04:00,PODD,neutral
1023097.0,Insulet shares are trading higher after the company reported better-than-expected Q1 financial results and raised 2019 sales guidance.,2019-05-03 09:58:00-04:00,PODD,positive
1023098.0,Insulet Raises FY19 Revenue Guidance From $662M-$687M To $667M-$690M Vs. $680.47M Estimate,2019-05-02 16:40:00-04:00,PODD,neutral
1023099.0,"Insulet Q1 EPS $0.07 Beats $0.01 Estimate, Sales $159.6M Beat $154.65M Estimate",2019-05-02 16:38:00-04:00,PODD,neutral
1023100.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,PODD,positive
1023101.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,PODD,positive
1023102.0,Shares of several medical device companies are trading lower with the healthcare sector. Healthcare has seen weakness recently due to concerns over the future of the Affordable Act under Trump and healthcare policy uncertainty ahead of the 2020 election.,2019-04-17 12:45:00-04:00,PODD,negative
1023103.0,Insulet Sees Q1 Sales $152M-$156M; FY19 Sales $662M-$687M,2019-02-25 16:02:00-05:00,PODD,neutral
1023104.0,"Insulet Q4 EPS $0.16 Beats $0.07 Estimate, Sales $164.9M Beat $162.46M Estimate",2019-02-25 16:01:00-05:00,PODD,neutral
1023105.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,PODD,neutral
1023106.0,Insulet Announces Wayde McMillan CFO,2019-01-07 07:08:00-05:00,PODD,neutral
1023107.0,"Morgan Stanley Maintains Equal-Weight on Insulet, Lowers Price Target to $90",2019-01-02 09:47:00-05:00,PODD,negative
1023108.0,"UBS Initiates Coverage On Insulet with Buy Rating, Announces $105 Price Target",2018-11-28 08:15:00-05:00,PODD,neutral
1023109.0,Insulet's Omnipod DASH Insulin Management System Receives ISO 27001 Certification For Information Security,2018-11-20 16:02:00-05:00,PODD,positive
1023110.0,Insulet Raises Q1 Sales Guidance from $154.50M-162.50M to $159.0M-164.0M vs $161.10M Est,2018-11-01 16:04:00-04:00,PODD,neutral
1023111.0,Insulet Raises FY2018 Sales Guidance from $547.0M-562.0M to $558.0M-563.0M vs $557.41M Est,2018-11-01 16:04:00-04:00,PODD,neutral
1023112.0,"Insulet Corporation Q3 EPS $0.03 Up From $(0.04) YoY, Sales $151.1M Beat $149.36M Estimate",2018-11-01 16:02:00-04:00,PODD,neutral
1023113.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,PODD,negative
1023114.0,"Once Again, Baird Predicts End To Tandem's 'Fantastic' Run",2018-09-14 10:24:00-04:00,PODD,neutral
1023115.0,"Stocks Which Set New 52-Week High Yesterday, September 11th",2018-09-12 12:17:00-04:00,PODD,neutral
1023116.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,PODD,negative
1023117.0,"Stocks Which Set New 52-Week High Friday, September 7th",2018-09-10 16:36:00-04:00,PODD,neutral
1023118.0,"Insulet Reports Pres, COO Shacey Petrovic Promoted To CEO",2018-09-10 16:15:00-04:00,PODD,positive
1023119.0,"Stocks That Made New 52-Week Highs Yesterday, September 6th",2018-09-07 16:47:00-04:00,PODD,neutral
1023120.0,"The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering",2018-09-07 07:55:00-04:00,PODD,neutral
1023121.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,PODD,neutral
1023122.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,PODD,neutral
1023123.0,Insulet Corp shares are trading down 6.3% premarket after the company missed Q2 sales estimates and issued weak Q3 guidance.,2018-08-03 08:52:00-04:00,PODD,negative
1023124.0,"Insulet Sees Q3 Sales $144.5M-$151.5M vs $154.2M Est., FY18 Sales $547M-$562M vs $577.75M Est,",2018-08-02 16:07:00-04:00,PODD,neutral
1023125.0,"Insulet Q2 EPS $(0.03) Beats $(0.13) Estimate, Sales $124.3M Miss $132.86M Estimate",2018-08-02 16:06:00-04:00,PODD,negative
1023126.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,PODD,positive
1023127.0,Q2 Earnings Outlook For Insulet,2018-08-02 08:42:00-04:00,PODD,neutral
1023128.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,PODD,neutral
1023129.0,Insulet Reports Partnership With Glooko To Connect Co.'s Omnipod System User Data With Glooko+diasend Across Europe,2018-07-12 16:02:00-04:00,PODD,neutral
1023130.0,Insulet Earlier Announced It Had Assumed Direct Commercial Operations In Europe For Sales Of Its Ominpod System As Of July 1st,2018-07-02 09:13:00-04:00,PODD,neutral
1023131.0,"Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi",2018-06-14 08:11:00-04:00,PODD,negative
1023132.0,"Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111",2018-06-13 07:48:00-04:00,PODD,negative
1023133.0,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",2018-06-12 08:47:00-04:00,PODD,positive
1023134.0,"Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study",2018-06-07 07:58:00-04:00,PODD,neutral
1023135.0,A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Factory Orders Data,2018-06-04 07:31:00-04:00,PODD,neutral
1023136.0,Insulet's Omnipod DASH Insulin Management System Receives FDA 510(k) Clearance,2018-06-04 06:10:00-04:00,PODD,neutral
1023137.0,"Insulet Q1 EPS $(0.11) Beats $(0.19) Estimate, Sales $123.58M Beat $121.7M Estimate",2018-05-03 16:19:00-04:00,PODD,neutral
1023138.0,"Benzinga's Top Upgrades, Downgrades For April 20, 2018",2018-04-20 09:16:00-04:00,PODD,positive
1023139.0,"Berenberg Initiates Coverage On Insulet with Buy Rating, Announces $100.00 Price Target",2018-04-20 07:41:00-04:00,PODD,neutral
1023140.0,"Benzinga's Top Upgrades, Downgrades For April 4, 2018",2018-04-04 09:45:00-04:00,PODD,positive
1023141.0,"Guggenheim Initiates Coverage On Insulet with Buy Rating, Announces $105.00 Price Target",2018-04-04 09:12:00-04:00,PODD,neutral
1023142.0,Form 4 Filing Late Friday Showed Insulet Director Fallon Sold Total of 10K Shares at Avg. Prices Ranging From $84.10 to $84.165,2018-03-19 09:20:00-04:00,PODD,positive
1023143.0,Insulet to Present Omnipod Clinical Data at Three Major European National Diabetes Congresses,2018-03-14 03:50:00-04:00,PODD,neutral
1023144.0,Analyst: Insulet On Track For Profitability In 2018,2018-03-06 11:51:00-05:00,PODD,positive
1023145.0,"BMO Capital Initiates Coverage On Insulet with Outperform Rating, Announces $90.00 Price Target",2018-03-06 07:05:00-05:00,PODD,neutral
1023146.0,"Cowen & Co. Maintains Outperform on Insulet, Raises price target to $90.00",2018-02-22 10:34:00-05:00,PODD,neutral
1023147.0,"Morgan Stanley Maintains Equal-Weight on Insulet, Raises price target to $87.00",2018-02-22 10:03:00-05:00,PODD,neutral
1023148.0,"Stephens & Co. Maintains Equal-Weight on Insulet, Raises price target to $81.00",2018-02-22 08:55:00-05:00,PODD,neutral
1023149.0,Insulet Sees Q1 Sales $119M-$123M vs $119.7M Est.; Sees FY18 Sales $560M-$580M vs $554.3M Est.,2018-02-21 16:27:00-05:00,PODD,neutral
1023150.0,"Insulet Reports Q4 EPS $(0.12) vs $(0.08) Est., Sales $130.5M vs $125.2M Est.",2018-02-21 16:26:00-05:00,PODD,neutral
1023151.0,Insulet Q4 Earnings Preview,2018-02-21 10:43:00-05:00,PODD,neutral
1023152.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-19 10:50:00-05:00,PODD,neutral
1023153.0,Insulet Gives New Data for its Omnipod Horizon,2018-02-14 06:09:00-05:00,PODD,neutral
1023154.0,"JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics",2018-01-09 09:02:00-05:00,PODD,positive
1023155.0,Ascensia Diabetes Care Reports Expansion Of Scope Of Strategic Alliance With Insulet,2018-01-09 08:02:00-05:00,PODD,positive
1023156.0,"Ascensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by Signing A Global Commercial Agreement,  Insulet To Distribute CONTOUR®NEXT ONE BGMS With Omnipod DASH",2018-01-09 07:04:00-05:00,PODD,positive
1023157.0,4 Tailwinds Driving Raymond James' Insulet Bull Case,2018-01-08 12:22:00-05:00,PODD,neutral
1023158.0,Cowen Expects CMS Coverage Of Insulet's Omnipod Drug Delivery System To Cause 'Revenue Estimates And The Stock To Go Higher',2018-01-08 10:05:00-05:00,PODD,neutral
1023159.0,Insulet Earlier Announced That CMS Will Allow Omnipod To Be Covered Under Medicare Part D,2018-01-08 10:03:00-05:00,PODD,positive
1023160.0,Raymond James Upgrades Insulet to Outperform,2018-01-08 08:04:00-05:00,PODD,neutral
1023161.0,"Piper Jaffray Healthcare Conference 2017 Begins Today, Presenters Include: Civitas Solutions, Insulet, ACADIA Healthcare, Nektar Therapeutics, Quidel, and Arrowhead Pharmaceuticals",2017-11-28 08:57:00-05:00,PODD,positive
1023162.0,"Barclays Maintains Overweight on Insulet, Raises Price Target to $75.00",2017-11-20 11:57:00-05:00,PODD,negative
1023163.0,55 Biggest Movers From Friday,2017-11-06 05:58:00-05:00,PODD,neutral
1023164.0,48 Stocks Moving In Friday's Mid-Day Session,2017-11-03 12:30:00-04:00,PODD,neutral
1023165.0,"Benzinga's Top Upgrades, Downgrades For November 3, 2017",2017-11-03 09:10:00-04:00,PODD,positive
1023166.0,"The Market In 5 Minutes: Apple, iPhones, And Trump's Twitter",2017-11-03 08:56:00-04:00,PODD,neutral
1023167.0,Canaccord Genuity Upgrades Insulet to Buy,2017-11-03 06:10:00-04:00,PODD,neutral
1023168.0,Insulet Sees Q4 Sales $123M-$126M vs $120.88M Est.; FY17 Sales Outlook Raised From $440M-$450M to $456M-$459M vs $447.09M Est.,2017-11-02 16:24:00-04:00,PODD,neutral
1023169.0,"Insulet Reports Q3 EPS $(0.04) vs $(0.10) Est., Sales $121.8M vs $114.41M Est.",2017-11-02 16:22:00-04:00,PODD,neutral
1023170.0,"Insulet, Dexcom Partner to Offer Choices for Animas Users",2017-10-18 16:04:00-04:00,PODD,neutral
1023171.0,Seeing Notable Block Trade In Insulet Of 729K Shares At $55.40/Share,2017-10-02 10:34:00-04:00,PODD,negative
1023172.0,"Barclays Initiates Coverage On Insulet with Overweight Rating, Announces $65.00 Price Target",2017-09-15 07:11:00-04:00,PODD,negative
1023173.0,"Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet",2017-08-15 08:40:00-04:00,PODD,neutral
1023174.0,"Insulet Raises FY17 Sales From $425-$440M to $440-$450M, Sees Q3 Sales $112-$116M vs $110M Est.",2017-08-03 16:02:00-04:00,PODD,neutral
1023175.0,"Insulet Reports Q2 EPS $(0.13) vs $(0.13) Est., Sales $109.8M vs $106.1M Est.",2017-08-03 16:02:00-04:00,PODD,neutral
1023176.0,Insulet Downgraded Despite Expectations For Strong Performance,2017-07-17 10:17:00-04:00,PODD,negative
1023177.0,"Benzinga's Top Upgrades, Downgrades For July 17, 2017",2017-07-17 09:30:00-04:00,PODD,positive
1023178.0,BTIG Research Downgrades Insulet to Neutral,2017-07-17 07:25:00-04:00,PODD,neutral
1023179.0,Insulet Reports 'Positive' Omnipod Horizon Study Data,2017-06-12 06:03:00-04:00,PODD,neutral
1023180.0,Insulet Names Bret Christensen as Chief Commercial Officer,2017-05-30 08:30:00-04:00,PODD,neutral
1023181.0,"Benzinga's Top Upgrades, Downgrades For May 10, 2017",2017-05-10 09:29:00-04:00,PODD,positive
1023182.0,BTIG Research Upgrades Insulet to Buy,2017-05-10 07:20:00-04:00,PODD,neutral
1023183.0,"Insulet Narrows, Raises FY17 Outlook: Sales from $420M-$440M to $425M-$440M vs $432M Est.",2017-05-08 16:04:00-04:00,PODD,neutral
1023184.0,Insulet Sees Q2 Sales $104M-$108M vs $104.6M Est.,2017-05-08 16:04:00-04:00,PODD,neutral
1023185.0,"Insulet Reports Q1 EPS $(0.17) vs $(0.15) Est., Sales $101.7M vs $97.8M Est.",2017-05-08 16:03:00-04:00,PODD,neutral
1023186.0,"Raymond James Institutional Investors Conference Continues Today; Presenters Include Arrow Electronics, Insulet, JB Hunt, HCA Holdings, Palo Alto, Alexion, Moody's, Pier 1, & ACADIA Pharama",2017-03-07 08:57:00-05:00,PODD,neutral
1023187.0,15 Biggest Mid-Day Losers For Monday,2017-03-06 13:15:00-05:00,PODD,negative
1023188.0,Insulet: 'Results Have Been Stellar But So Has The Share Reaction',2017-03-06 09:52:00-05:00,PODD,positive
1023189.0,"Benzinga's Top Upgrades, Downgrades For March 6, 2017",2017-03-06 09:48:00-05:00,PODD,positive
1023190.0,"Cowen Annual Healthcare Conference Begins Today; Presenters Include Insulet, PARAXEL, Zoetis, Alexion, Bristol-Myers, Acadia, Alnylam, Axovant, Ardelyx, Aurinia Pharma, And Puma Biotech",2017-03-06 08:39:00-05:00,PODD,neutral
1023191.0,BTIG Research Downgrades Insulet To Neutral,2017-03-06 06:41:00-05:00,PODD,neutral
1023192.0,"Insulet Reports Q4 EPS $(0.16) vs. $(0.05) Est., Sales $103.57M vs. $100M Est.",2017-02-27 16:05:00-05:00,PODD,neutral
1023193.0,Insulet Presents Strong Omnipod Horizon Hybrid Closed-Loop Study Results at ATTD in Paris,2017-02-17 06:04:00-05:00,PODD,positive
1023194.0,DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage,2017-01-13 16:12:00-05:00,PODD,neutral
1023195.0,"JP Morgan Healthcare Conf. Begins Today; Presenters Include Insulet, Teladoc, Incyte, Johnson & Johnson, Acadia Healthcare, & Teva Pharmaceuticals",2017-01-09 08:49:00-05:00,PODD,positive
1023196.0,The MedTech Group: 2017 Top Picks And Catalysts,2017-01-06 10:35:00-05:00,PODD,positive
1023197.0,7 Biggest Price Target Changes For Friday,2017-01-06 09:58:00-05:00,PODD,neutral
1023198.0,"Baird Upgrades Insulet to Outperform, Raises Target to $47.00",2017-01-06 07:10:00-05:00,PODD,neutral
1023199.0,GradientAnalytics Tweets: Gradient issues 22 page earnings quality Alert on Insulet Corp $PODD by senior analyst Daniel Stone.,2017-01-05 13:34:00-05:00,PODD,positive
1023200.0,Insulet Shares Down ~$0.45 Over Last Min as Hearing Gradient Has Issued 22-Page Short Report on Name,2017-01-05 13:34:00-05:00,PODD,positive
1023201.0,Volume Spike in Insulet,2016-12-28 14:13:00-05:00,PODD,neutral
1023202.0,"SkyTides Sends Numerous Tweets on Insulet, Including: '$PODD CEO's purchase amounts to likely less than 1% of his net worth he made $100M on sale of last company'",2016-12-06 11:01:00-05:00,PODD,positive
1023203.0,Insulet's CEO Lets His Money Do The Talking,2016-12-05 10:49:00-05:00,PODD,neutral
1023204.0,"INSULET CORP: SULLIVAN PATRICK J (Director, CEO and Chairman of the Board) Buys 40,000 @ Avg Price: $33.89 (Form4)",2016-12-05 08:42:00-05:00,PODD,neutral
1023205.0,Insulet Corp. CEO Patrick Sullivan Acquires 40K Shares Between $33.089 To $34/Share,2016-12-05 08:39:00-05:00,PODD,positive
1023206.0,SkyTides Tweets: $PODD perhaps the most suspect management team we've seen since that China thing,2016-12-02 11:05:00-05:00,PODD,negative
1023207.0,"UPDATE: Comment from Insulet's Petrovic Which Medtronic Exec Found to be Misinformation At Best was Related to Insulet Being 'laser-focused on new patient starts coming from MDI patients, not from patients already using competitive pump...'",2016-12-02 11:03:00-05:00,PODD,positive
1023208.0,SkyTides: Insulet's President Provided 'Critical Misinformation To Investors',2016-12-02 11:01:00-05:00,PODD,negative
1023209.0,Benzinga Obtains Copy of Latest Update from SkyTides on Insulet; Report Shows Comment from Medtronic Exec Suggesting Recent Comment Related MDI Patients from Insulet Pres Petrovic 'was at a Minimum Misinformation',2016-12-02 11:00:00-05:00,PODD,negative
1023210.0,Letter To Massachusetts Attorney General Outlines Undisclosed Insulet Omnipod Patient Deaths,2016-11-30 15:42:00-05:00,PODD,neutral
1023211.0,"UPDATE: Of The 44 Patient Deaths That Have Been Uncovered, SkyTides Alleges That Company Failed To Confirm 19 Of These Deaths",2016-11-30 15:01:00-05:00,PODD,negative
1023212.0,"UPDATE: SkyTides Letter to AG Outlines Uncovered Evidence of Patient Death Cover Up, Pay Off of Whistleblower Related to Insulet's Omnipod Device",2016-11-30 14:59:00-05:00,PODD,negative
1023213.0,"In a Letter To Attorney General Mura Healey Obtained By Benzinga, SkyTides Alleges Insulet's Omnipod Device Puts 100K Patients At Risk Of Serious Harm Or Death. SkyTides Says To Date, 44 Patient Deaths Have Been Uncovered, With Co. Failing To Confirm 19 o",2016-11-30 14:59:00-05:00,PODD,negative
1023214.0,"Prescience Point Tweets: 1) New $PODD report reveals evidence that adds to our assessment --> $PODD is a STRONG SELL. To reiterate, we are short with a PT: $20",2016-11-29 13:12:00-05:00,PODD,positive
1023215.0,"UPDATE: New Info in Insulet Report by SkyTides Includes: Medtronic's 670G is 'Legitimate Near-Term, Long-Term Threat to All Insulin Pump Manufacturers, Allegations from Another Whistleblower",2016-11-29 10:46:00-05:00,PODD,negative
1023216.0,New Report Questions Insulet Management's 'Baseless' Claims: 'Investors Being Led To The Slaughter',2016-11-29 10:16:00-05:00,PODD,neutral
1023217.0,"BZ NOTE: Insulet Shares Had Ben Trading Around $35 Ahead of SkyTides Report, SkyTides' $15 Price Target Implies Potential Downside of 57%",2016-11-29 10:15:00-05:00,PODD,positive
1023218.0,"Benzinga Obtains Copy of Negative Report from SkyTides: 'Insulet Investors Being Led to the Slaughter by CEO Recently Accused of Misleading Investors, Illegal Acts, Bribes, Price Target $15'",2016-11-29 10:14:00-05:00,PODD,negative
1023219.0,UPDATE: SkyTides Release Highlights 5 Topics From Initial Report 'Not Addressed By Insulet Management',2016-11-17 12:20:00-05:00,PODD,neutral
1023220.0,SkyTides Releases Follow Up To Previous Short-Report,2016-11-17 12:18:00-05:00,PODD,neutral
1023221.0,Prescience Point Tweets: @podd: Evidence of patient deaths and paying off whistleblower(s) to cover up is especially frightening in light of FDA investigation,2016-11-16 10:51:00-05:00,PODD,negative
1023222.0,"Prescience Point Tweets: 1) Props to @SkyTides for the research published yesterday on $PODD. We've also researched the opaque company, believe it is a STRONG SELL",2016-11-16 10:50:00-05:00,PODD,positive
1023223.0,"Companies Holding Analyst/Investor Days Today Include Noble Energy, Insulet Corp, & New Relic",2016-11-16 09:48:00-05:00,PODD,positive
1023224.0,"Insulet Shares Edge Lower as Hearing Skytides Issued Negative Research: 'Insulet: Undisclosed Patient Deaths ""Life-Threatening, Especially for Children,"" Price Target $15'",2016-11-15 10:01:00-05:00,PODD,negative
1023225.0,25 Biggest Mid-Day Gainers For Friday,2016-11-04 12:43:00-04:00,PODD,neutral
1023226.0,Benzinga's Volume Movers,2016-11-04 10:40:00-04:00,PODD,neutral
1023227.0,"BTIG Research Upgrades Insulet Corporation - Common Stock to Buy, Announces $42.00",2016-11-04 06:54:00-04:00,PODD,neutral
1023228.0,"Insulet Raises FY16 Rev. From $345-$355M To $362-$365M, Q4 Rev. $99-$102M vs. Est. $93M",2016-11-03 16:30:00-04:00,PODD,neutral
1023229.0,"Insulet Reports Q3 EPS $(0.05) vs. Est. $(0.09), Rev. $94.9M vs. Est. $89.7M",2016-11-03 16:29:00-04:00,PODD,neutral
1023230.0,Insulet Promotes Shacey Petrovic To Chief Operating Officer,2016-10-19 16:04:00-04:00,PODD,positive
1023231.0,"Insulet Announces Pres, CEO, Patrick Sullivan, Named as Chair",2016-10-19 16:03:00-04:00,PODD,neutral
1023232.0,"B. Riley Initiates Coverage on Insulet at Neutral, Announces $46.00 PT",2016-09-27 04:01:00-04:00,PODD,neutral
1023233.0,10 Stocks Which Rallied Three Days On Increasing Volume,2016-09-19 09:26:00-04:00,PODD,neutral
1023234.0,Insulet Enrolls First Patients in Onipod Trial,2016-09-13 06:03:00-04:00,PODD,neutral
1023235.0,Insulet Establishes Manufacturing Operation in the US,2016-09-06 07:33:00-04:00,PODD,neutral
1023236.0,20 Biggest Mid-Day Gainers For Thursday,2016-08-04 12:49:00-04:00,PODD,neutral
1023237.0,Benzinga's Volume Movers,2016-08-04 10:47:00-04:00,PODD,neutral
1023238.0,"After-Hours Gainers Aug. 3, '16: OCUL Up 22%, SQ 14.9%, CBMX 13.5%, AXGN 10%, AVID 8.7%, PODD 8.6%, NSTG 8.3%, JACK 8%, EXEL 7.7%",2016-08-03 19:10:00-04:00,PODD,positive
1023239.0,Insulet Raises FY16 Guidance From $330-$350M To $345-$355M,2016-08-03 16:21:00-04:00,PODD,neutral
1023240.0,"Insulet Reports Q2 EPS $(0.08) vs. Est. $(0.17), Rev. $87.3M vs. Est. $81.19M",2016-08-03 16:20:00-04:00,PODD,neutral
1023241.0,BMO Capital Highlights This Week's MedTech Earnings,2016-08-01 15:14:00-04:00,PODD,neutral
1023242.0,Option Alert: PODD Sep16 30.0 Calls: 1000 @  ASK  $2.15: 1000 traded vs 1004 OI: $27.18 Ref,2016-05-12 10:25:00-04:00,PODD,positive
1023243.0,UPDATE: Insulet Sees Q2 Sales $81M-$84M vs $81.2M Est.; Sees FY16 Sales $330M-$350M vs $337.5M Est.,2016-05-03 14:36:00-04:00,PODD,neutral
1023244.0,"Insulet Reaffirms Q2, FY16 Outlook",2016-05-03 14:35:00-04:00,PODD,neutral
1023245.0,The Market In 5 Minutes: You're Not Your Job,2016-04-29 09:40:00-04:00,PODD,neutral
1023246.0,Benzinga's Top Upgrades,2016-04-29 08:58:00-04:00,PODD,positive
1023247.0,William Blair Upgrades Insulet to Outperform,2016-04-29 06:28:00-04:00,PODD,neutral
1023248.0,"Insulet Sees FY16 Rev. $330-$350M vs. Est. $341M, Q2 Rev. $81-$84M vs. Est. $82M",2016-04-28 16:15:00-04:00,PODD,neutral
1023249.0,"Insulet Corp. Reports Q1 EPS $(0.19) vs. Est. $(0.19), Rev. $81.2M vs. Est. $79M",2016-04-28 16:15:00-04:00,PODD,neutral
1023250.0,Benzinga's Top Upgrades,2016-02-26 09:05:00-05:00,PODD,positive
1023251.0,Benchmark Upgrades Insulet to Buy,2016-02-26 06:21:00-05:00,PODD,neutral
1023252.0,"Insulet Reports Q4 EPS $(0.48) vs. Est. $(0.26), Rev. $100.119M vs. Est. $91.89M",2016-02-25 16:26:00-05:00,PODD,neutral
1023253.0,"Sell Insulet, Empire Warns",2016-02-25 09:42:00-05:00,PODD,negative
1023254.0,Benzinga's Top Initiations,2016-02-25 09:35:00-05:00,PODD,positive
1023255.0,"Empire Asset Management CO Initiates Coverage on Insulet at Sell, Announces $15.00 PT",2016-02-25 07:57:00-05:00,PODD,positive
1023256.0,Insulet Announces Will Divest Neighborhood Diabetes Supplies Unit to Liberty Medical for $5M in Cash,2016-02-02 16:23:00-05:00,PODD,positive
1023257.0,"Insulet Enters Agreement With Eli Lilly For OmniPod Delivery Of U200 Concentrated Insulin, Terms Not Dislcosed",2016-01-11 17:01:00-05:00,PODD,positive
1023258.0,UPDATE: Insult Corp To Supply IS OmniPad Patients & Health Providers With New Data System In New Glooko Partnership,2016-01-05 17:15:00-05:00,PODD,negative
1023259.0,Insulet Partners with Glooko as its Preferred Data Management Partner for OmniPod Patients and Healthcare Providers,2016-01-05 17:14:00-05:00,PODD,neutral
1023260.0,MannKind's New Man In Charge,2015-12-24 10:59:00-05:00,PODD,neutral
1023261.0,"Insulet Shares Up 10% Despite Reporting Q3 EPS $(0.33) vs $(0.25) Est., Sales $87.3M vs $89M Est.",2015-11-06 10:45:00-05:00,PODD,positive
1023262.0,"Morgan Stanley Initiates Coverage on Insulet at Equal-weight, Announces $32.00 PT",2015-11-02 09:46:00-05:00,PODD,neutral
1023263.0,Shares That Spiked Before Close,2015-10-16 16:02:00-04:00,PODD,positive
1023264.0,"Insulet Reports Q2 ePS $(0.27) vs. Est. $(0.13), Rev. $75.6M vs. Est. $70.75M",2015-08-12 16:01:00-04:00,PODD,neutral
1023265.0,"Earnings Scheduled For August 12, 2015",2015-08-12 04:22:00-04:00,PODD,neutral
1023266.0,"Baird Initiates Coverage on Insulet at Neutral, Announces $34.00 PT",2015-07-08 07:14:00-04:00,PODD,neutral
1023267.0,Insulet Corporation Assumes Distribution Rights for OmniPod System in Canada,2015-07-07 16:31:00-04:00,PODD,neutral
1023268.0,Insulet Corp. Receives FDA Warning Regarding Conformity WIth Current Good Manufacturing Requirements of the Quality System Regulation,2015-06-10 17:13:00-04:00,PODD,positive
1023269.0,"Insulet CEO Sullivan Buys 10,000 Shares @$29.39/Share -Form 4",2015-06-08 07:25:00-04:00,PODD,positive
1023270.0,Northland Securities Upgrades Insulet to Outperform,2015-05-04 07:01:00-04:00,PODD,positive
1023271.0,Stocks Hitting 52-Week Lows,2015-05-01 10:47:00-04:00,PODD,negative
1023272.0,"Thursday's After-Hours Movers: NutriSystem, LinkedIn And More",2015-04-30 18:09:00-04:00,PODD,neutral
1023273.0,13G Filing Shows Insulet Holder PrimeCap mgmt Reports 5.02% Stake Up From 3.5%,2015-04-07 12:56:00-04:00,PODD,neutral
1023274.0,Wedbush Securities Sees Insulet Strengthen Bench By Hiring Experienced CFO,2015-03-31 09:08:00-04:00,PODD,positive
1023275.0,Insulet Names Michael Levitz CFO,2015-03-30 16:01:00-04:00,PODD,neutral
1023276.0,Oppenheimer Downgrades Insulet to Perform,2015-02-27 07:16:00-05:00,PODD,neutral
1023277.0,"Insulet Reports Q4 EPS $(0.10), Rev. $72.6M",2015-02-26 16:12:00-05:00,PODD,neutral
1023278.0,Insulet Corporation to Assume Distribution Rights for OmniPod System in Canada,2015-02-26 08:04:00-05:00,PODD,neutral
1023279.0,Canaccord Genuity Downgrades Insulet To Hold,2015-02-18 09:09:00-05:00,PODD,neutral
1023280.0,Benzinga's Top Downgrades,2015-02-18 08:53:00-05:00,PODD,positive
1023281.0,"Canaccord Genuity Downgrades Insulet to Hold, Lowers PT to $35.00",2015-02-18 06:44:00-05:00,PODD,negative
1023282.0,"Oppenheimer Reiterates Rating, Lowers Price Target On Insulet As New Management Begins Executing Plan",2015-01-16 09:39:00-05:00,PODD,negative
1023283.0,"JP Morgan Downgrades Insulet to Neutral, Lowers PT to $35.00",2015-01-15 05:37:00-05:00,PODD,positive
1023284.0,Mid-Morning Market Update: Markets Jump; Family Dollar Profit Misses Estimates,2015-01-08 11:39:00-05:00,PODD,positive
1023285.0,Morning Market Losers,2015-01-08 09:54:00-05:00,PODD,negative
1023286.0,Benzinga's Top #PreMarket Losers,2015-01-08 08:22:00-05:00,PODD,negative
1023287.0,Wednesday's After-Hours Movers,2015-01-07 17:49:00-05:00,PODD,neutral
1023288.0,Insulet Lowers FY2014 Sales Guidance from $292.0M-297.0M to $287.0M-289.0M vs $296.0M Est,2015-01-07 16:17:00-05:00,PODD,negative
1023289.0,"Insulet Lowers Q4 Sales Guidance from $76.0M-81.0M to $71.0M-73.0M vs $79.50M Est, Cites Delay in Shipments",2015-01-07 16:16:00-05:00,PODD,negative
1023290.0,"Cowen & Company Initiates Coverage on Insulet Corporation at Outperform, Announces $53.00 PT",2014-12-08 06:24:00-05:00,PODD,neutral
1023291.0,"Insulet Corporation Appoints Allison Dorval As CFO; Brad Thomas As EVP, HR & Organizational Development ",2014-11-05 16:26:00-05:00,PODD,neutral
1023292.0,Insulet Corporation Reports Q3 EPS of $0.00 vs $(0.01) Est; Revenue of $75.0M vs $75.31M Est,2014-11-05 16:23:00-05:00,PODD,neutral
1023293.0,Lennar Gains On Upbeat Earnings; Adobe Shares Slide,2014-09-17 12:37:00-04:00,PODD,positive
1023294.0,Insulet Reaffirms Q3 Sales Guidance,2014-09-16 16:31:00-04:00,PODD,neutral
1023295.0,"Insulet Names Patrick Sullivan as Pres, CEO",2014-09-16 16:30:00-04:00,PODD,neutral
1023296.0,Insulet Corporation Sees FY2014 Sales $290.0M-300.0M,2014-08-07 16:39:00-04:00,PODD,neutral
1023297.0,Insulet Corporation Sees Q3 Sales $73.0M-77.0M,2014-08-07 16:39:00-04:00,PODD,neutral
1023298.0,Insulet Corporation Reports Q2 EPS of $(0.53) Which May Not Compare $(0.08) Est; Revenue of $72.0M Which May Not Compare $72.94M Est,2014-08-07 16:38:00-04:00,PODD,neutral
1023299.0,Insulet to Pay $5M To BD In Patent Suit,2014-06-27 16:52:00-04:00,PODD,negative
1023300.0,Insulet Announces Offering of Convertible Notes Worth $175M,2014-06-03 16:03:00-04:00,PODD,positive
1023301.0,"Barrington Research Upgrades Insulet Corporation to Outperform, Announces $40.00 PT",2014-05-16 06:25:00-04:00,PODD,neutral
1023302.0,Despite Weak earnings Feltl & Co. Upgraded Insulet Corporation to Hold,2014-05-08 11:20:00-04:00,PODD,positive
1023303.0,Insulet Corporation Sees Q2 Sales $70.40M-74.0M vs $73.86M Est,2014-05-07 17:26:00-04:00,PODD,neutral
1023304.0,Insulet Corporation Reports Q1 EPS of $(0.11) vs $(0.06) Est; Revenue of $69.20M vs $68.47M Est,2014-05-07 17:24:00-04:00,PODD,neutral
1023305.0,Insulet Appoints Patrick Ryan as Chief Operating Officer ,2014-01-21 16:16:00-05:00,PODD,neutral
1023306.0,Form 8-K from Insulet Shows W. Mark Lortz Resigned as Director,2013-12-11 17:05:00-05:00,PODD,negative
1023307.0,"Raymond James Upgrades Insulet Corporation to Outperform, Announces $43.00 PT",2013-11-22 07:30:00-05:00,PODD,neutral
1023308.0,Insulet Corporation Reports Q3 EPS of $(0.39) vs $(0.16) Est; Revenue of $61.10M vs $62.01M Est,2013-11-07 16:19:00-05:00,PODD,neutral
1023309.0,UPDATE: Benchmark Initiates Coverage on Insulet Corporation Following Strong Response to New OmniPod,2013-10-15 11:30:00-04:00,PODD,positive
1023310.0,Benzinga's Top Initiations,2013-10-15 07:46:00-04:00,PODD,positive
1023311.0,"Benchmark Initiates Coverage on Insulet Corporation at Buy, Announces $44.00 PT",2013-10-15 06:31:00-04:00,PODD,neutral
1023312.0,Form 8-K from Insulet Shows Co. Entered Settlement Deal with Medtronic Related to Infringement Suit,2013-09-25 16:10:00-04:00,PODD,negative
1023313.0,"JMP Securities Downgrades Insulet Corporation to Market Perform, Removes $33.00 PT",2013-09-20 08:21:00-04:00,PODD,positive
1023314.0,"Wunderlich Suspends Hold Rating on Insulet Corporation, Removes $28.00 PT",2013-08-08 07:20:00-04:00,PODD,neutral
1023315.0,Insulet Corporation Reports Q2 EPS of $(0.20) vs $(0.19) Est; Revenue of $60.10M vs $60.46M Est,2013-08-07 16:10:00-04:00,PODD,neutral
1023316.0,Northland Securities Downgrades Insulet Corporation to Underperform,2013-07-18 08:20:00-04:00,PODD,positive
1023317.0,UPDATE: Canaccord Genuity Raises PT on Insulet Following Investor Conference,2013-06-24 10:38:00-04:00,PODD,neutral
1023318.0,"Canaccord Genuity Maintains Buy on Insulet Corporation, Raises PT to $37.00",2013-06-24 10:00:00-04:00,PODD,neutral
1023319.0,"Feltl & Co. Downgrades Insulet Corp. from Buy to Hold, Raises Target from $28 to $33",2013-06-20 14:05:00-04:00,PODD,neutral
1023320.0,UPDATE: Wunderlich Securities Downgrades Insulet to Hold as Shares Exceed Price Target,2013-06-07 10:06:00-04:00,PODD,positive
1023321.0,Benzinga's Top Downgrades,2013-06-07 07:36:00-04:00,PODD,positive
1023322.0,"Wunderlich Downgrades Insulet Corporation to Hold, Maintains $28.00 PT",2013-06-07 07:10:00-04:00,PODD,neutral
1023323.0,UPDATE: Barrington Downgrades Insulet to Market Perform Following on Valuation,2013-05-09 08:31:00-04:00,PODD,neutral
1023324.0,Barrington Research Downgrades Insulet Corporation to Market Perform,2013-05-08 15:59:00-04:00,PODD,neutral
1023325.0,"Northland Securities Downgrades Insulet Corporation to Market Perform, Maintains $28.00 PT",2013-05-08 08:36:00-04:00,PODD,positive
1023326.0,Insulet Corporation Reports Q1 EPS of $(0.20) vs $(0.21) Est; Revenue of $57.40M,2013-05-06 16:21:00-04:00,PODD,neutral
1023327.0,"Raymond James Downgrades Insulet Corporation to Market Perform, Removes $25.00 PT",2013-05-02 07:19:00-04:00,PODD,neutral
1023328.0,Insulet Corporation Sees FY2013 Sales $240.0M-255.0M vs $263.0M Est,2013-02-27 16:24:00-05:00,PODD,neutral
1023329.0,"Insulet Corporation Reports Q4 EPS of $(0.21), Inline; Revenue of $57.80M",2013-02-27 16:22:00-05:00,PODD,neutral
1023330.0,"UPDATE: Canaccord Genuity Reiterates Buy Rating, Lowers PT on Insulet Corporation Ahead of 4Q12 Results",2013-02-22 14:45:00-05:00,PODD,negative
1023331.0,"J.P. Morgan Reiterates Overweight Rating, $26 PT on Insulet Corporation on Updated Estimates",2013-02-15 14:48:00-05:00,PODD,negative
1023332.0,Insulet Sees Proceeds of $80.6M from Offering,2013-01-04 10:47:00-05:00,PODD,neutral
1023333.0,Insulet Announces Offering of $85M in Stock,2013-01-03 16:25:00-05:00,PODD,neutral
1023334.0,"UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Insulet Corporation",2012-12-21 10:11:00-05:00,PODD,neutral
1023335.0,"Canaccord Genuity Maintains Buy on Insulet Corporation, Raises PT to $29.00",2012-12-21 08:08:00-05:00,PODD,neutral
1023336.0,UPDATE: Jefferies Raises PT to $25 on Insulet Following Eros FDA Approval  ,2012-12-17 13:08:00-05:00,PODD,positive
1023337.0,"From Earlier: Stephens & Co. Downgrades Insulet Corporation to Equalweight, Maintains $24.00 PT",2012-12-17 12:44:00-05:00,PODD,neutral
1023338.0,UPDATE: Piper Jaffray Upgrades Insulet Corporation to Overweight on Next Generation Approval  ,2012-12-17 09:57:00-05:00,PODD,positive
1023339.0,"Piper Jaffray Upgrades Insulet Corporation to Overweight, Raises PT to $27.00",2012-12-17 05:59:00-05:00,PODD,negative
1023340.0,"Jefferies Maintains Buy on Insulet Corporation, Raises PT to $25.00",2012-12-14 15:31:00-05:00,PODD,neutral
1023341.0,Insulet Corporation Gets Approval for OmniPod Pump,2012-12-14 10:18:00-05:00,PODD,positive
1023342.0,Insulet Appoints John A. Fallon to Board of Directors ,2012-10-25 16:43:00-04:00,PODD,neutral
1023343.0,"UPDATE: Wunderlich Securities Reiterates Buy Rating, Raises PT on Insulet Corporation",2012-08-29 13:20:00-04:00,PODD,positive
1023344.0,"Wunderlich Securities Maintains Insuletoration at Buy, Raises PT from $22 to $24",2012-08-29 05:51:00-04:00,PODD,positive
1023345.0,"Feltl and Company Maintains Insuletoration at Buy, Raises PT from $22.10 to $24",2012-08-09 08:40:00-04:00,PODD,neutral
1023346.0,"Jefferies & Company Maintains Insuletoration at Buy, Lowers PT from $24 to $23",2012-08-09 07:39:00-04:00,PODD,negative
1023347.0,"Canaccord Maintains Insuletoration at Buy, Lowers PT from $27 to $24.50",2012-08-09 06:41:00-04:00,PODD,negative
1023348.0,"Insulet Guides FY Revenue $210-220M, Had Seen $210-225M vs $216.1M Est; Guides Q3 Revenue $53-57M vs $55.9M Est",2012-08-08 16:52:00-04:00,PODD,neutral
1023349.0,Insulet Reports Q2 EPS $-0.30 vs $-0.26 Est; Revenues $51M vs $52.09M Est,2012-08-08 16:51:00-04:00,PODD,neutral
1023350.0,"Oppenheimer Holdings Reiterates Outperform Rating, $24 PT for Insulet Corporation",2012-06-22 10:19:00-04:00,PODD,neutral
1023351.0,"Oppenheimer Maintains Insuletoration at Outperform, Raises PT to $24",2012-06-22 07:19:00-04:00,PODD,neutral
1023352.0,Insuletoration Reports Q1 EPS $-0.31 vs $-0.28 Est; Revenues $47.8M vs $47.46M Est,2012-05-09 16:21:00-04:00,PODD,neutral
1023353.0,Insulet Expands International Distribution Partnership With Ypsomed  ,2012-04-11 16:30:00-04:00,PODD,positive
1023354.0,"Insulet Announces Global Agreement With LifeScan, Inc to Integrate Their OneTouch Blood Glucose Monitoring Technologies Into the OmniPod Insulin Pump  ",2012-02-15 16:15:00-05:00,PODD,positive
1023355.0,UPDATE: Feltl & Company Raises PT to $22.10 on Insulet ,2012-02-13 12:40:00-05:00,PODD,neutral
1023356.0,"Feltl and Company Maintains Insuletoration at Buy, Raises PT from $18.6 to $22.1",2012-02-13 08:18:00-05:00,PODD,neutral
1023357.0,UPDATE: Jefferies Raises Target on Insulet to $24,2012-02-10 11:12:00-05:00,PODD,neutral
1023358.0,"Wunderlich Securities Reiterates Buy, $22 Target on Insulet Corporation",2012-02-10 08:46:00-05:00,PODD,positive
1023359.0,"Yesterday, Insulet Corporation Reports Q4 EPS $(0.30) vs $(0.26) Est; Revenues $47.2M vs $47.44M Est			 ",2012-02-10 06:41:00-05:00,PODD,neutral
1023360.0,"UPDATE: Brean Murray Carret Initiates Buy, $24 Target on Insulet",2012-01-17 10:52:00-05:00,PODD,neutral
1023361.0,Brean Murray Initiates Insulet at Buy,2012-01-17 07:23:00-05:00,PODD,neutral
1023362.0,Oppenheimer Reiterates Outperform on Insulet,2012-01-11 08:08:00-05:00,PODD,neutral
1023363.0,"JP Morgan Reiterates OW, Target of $24 on Insulet Corp ",2011-11-11 08:04:00-05:00,PODD,positive
1023364.0,Barrington Reiterates OUTPERFORM Rating on Insulet ,2011-11-07 08:05:00-05:00,PODD,neutral
1023365.0,Wunderlich Securities Maintains Buy Rating and $22 PT on Insulet  ,2011-11-04 09:35:00-04:00,PODD,positive
1023366.0,UPDATE: Jefferies Lowers PT to $21 on Insulet ,2011-11-04 08:12:00-04:00,PODD,negative
1023367.0,Jefferies Lowers PT on Insulet to $21,2011-11-04 07:30:00-04:00,PODD,negative
1023368.0,UPDATE: J.P. Morgan Lowers Price Target on Insulet to $24,2011-11-04 07:21:00-04:00,PODD,negative
1023369.0,JP Morgan Lowers PT on Insulet to $24,2011-11-04 06:34:00-04:00,PODD,positive
1023370.0,Hearing Insulet Corporation Initiated with Buy at Feltl & Company,2011-09-30 08:40:00-04:00,PODD,neutral
1023371.0,Wunderlich Securities Initiates Coverage on Insulet with a Buy Rating,2011-09-23 07:08:00-04:00,PODD,positive
1023372.0,Rodman & Renshaw Upgrades Insulet,2011-08-03 15:01:00-04:00,PODD,neutral
1023373.0,Jefferies Reports 2Q Sales On Insulet,2011-08-03 08:08:00-04:00,PODD,neutral
1023374.0,Jefferies Raises PT On Insulet Corporation To $25,2011-08-03 06:20:00-04:00,PODD,neutral
1023376.0,Rodman & Renshaw Downgrades Insulet from Market Perform to Underperform,2011-07-25 08:37:00-04:00,PODD,neutral
1023377.0,Stocks to Watch for 07/1/11: Fresh 52 Week Highs and Lows,2011-07-01 04:16:00-04:00,PODD,positive
1023378.0,Insulet Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock Issued in Previously Announced Neighborhood Diabetes Acquisition ,2011-06-24 08:02:00-04:00,PODD,neutral
1023379.0,Insulet Announces Concurrent Public Offerings of Notes and Common Stock Issued in Previously Announced Neighborhood Diabetes Acquisition ,2011-06-22 16:23:00-04:00,PODD,neutral
1023380.0,Jefferies Maintains Buy on Insulet,2011-06-09 08:19:00-04:00,PODD,neutral
1023381.0,"Oppenheimer Maintains OP Rating, $25 PT on Insulet Corporation",2011-06-07 09:08:00-04:00,PODD,neutral
1023382.0,Jefferies' Updates 6/3,2011-06-03 09:58:00-04:00,PODD,neutral
1023383.0,Jefferies Raises PT On PODD To $24,2011-05-10 08:26:00-04:00,PODD,neutral
1023384.0,UPDATE: Jefferies Raises PT on Insulet to $24 (PODD),2011-05-10 07:44:00-04:00,PODD,neutral
1023385.0,Jefferies Raises PT On Insulet Corporation To $24,2011-05-10 06:58:00-04:00,PODD,neutral
1023386.0,Jefferies Raising Price Target On Insulet Corp (PODD),2011-02-16 07:23:00-05:00,PODD,neutral
1023387.0,JMP Securities Downs PODD To Market Perform,2011-02-16 06:50:00-05:00,PODD,positive
1023388.0,Jefferies Raises PT On Insulet Corporation To $20,2011-02-16 06:39:00-05:00,PODD,neutral
1023389.0,Insulet Appoints Charles Liamos as COO  ,2011-01-10 17:00:00-05:00,PODD,neutral
1023390.0,Takeover Candidates In Medical Tech ,2010-12-20 14:31:00-05:00,PODD,neutral
1023391.0,Insulet Announces Early Repayment of $32.5M Facility Agreement  ,2010-12-14 16:21:00-05:00,PODD,positive
1023392.0,Insulet Corporation Announces the Sale of 3M Shares ,2010-12-07 16:19:00-05:00,PODD,positive
1023393.0,"Insulet Initiated At Buy, Revenues Expected To Double",2010-12-03 08:17:00-05:00,PODD,neutral
1023394.0,Jefferies Initiates Coverage on Insulet Corp. (NASDAQ: PODD),2010-12-03 07:48:00-05:00,PODD,neutral
1023395.0,J.P. Morgan Updates Estimates on Insulet Corp. (PODD),2010-12-01 09:56:00-05:00,PODD,neutral
1023396.0,J.P. Morgan Lowers Price Target On Insulet Corp (PODD),2010-11-10 07:44:00-05:00,PODD,negative
1023397.0,"Benzinga’s Volume Movers (VTIV, TESO, NILE, TTMI, PODD)",2010-05-07 15:59:00-04:00,PODD,neutral
1023398.0,"Benzinga’s Top Upgrades (JASO, MEA, SANM, WFR, PODD)",2010-05-07 10:04:00-04:00,PODD,positive
1023399.0,Insulet Corporation (PODD) Maintains Buy Rating,2010-03-08 16:16:00-05:00,PODD,neutral
1023400.0,Insulet Corporation’s (PODD) Fourth-Quarter Review,2010-02-10 15:39:00-05:00,PODD,neutral
1023401.0,"PODD Reports Strong Q4 Results, Issues Achievable Guidance",2010-02-10 10:48:00-05:00,PODD,positive
1023402.0,Soleil Securities Upgrades Insulet Corporation (NASDAQ: PODD),2009-11-20 10:34:00-05:00,PODD,positive
1023403.0,"After-Hours Top Losers (FSLR, HLIT, PODD, AFFX) ",2009-10-28 18:50:00-04:00,PODD,negative
1023404.0,"Benzinga’s Top Upgrades (COG, VZ, PODD, TXN)",2009-10-27 11:35:00-04:00,PODD,positive
